TriSalus Life Sciences, Inc.
TLSI
Positions held
Your positionsTLSI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $254.30M | Enterprise value | $242.44M | Trailing P/E | — | Forward P/E | -16.52 |
| PEG | — | Price / book | 38.60 | Beta | 0.47 | Dividend yield | 0.00% |
| Revenue growth | 1.7% | Earnings growth | — | Gross margin | 85.8% | Operating margin | -86.0% |
| Profit margin | -62.6% | ROE | — | ROA | -36.8% | Debt / equity | 5.26 |
| Current ratio | 5.35 | Free cash flow | -$10.88M | Analyst recommendation | none | Mean target | $10.40 |
| 52w high | $7.95 | 52w low | $2.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $11.4M | $8.9M | $13.2M | $11.6M | $11.2M | — |
| Op margin | -86.0% | -94.5% | -24.8% | -77.9% | -65.4% | — |
| Net income | -$9.2M | $1.5M | -$9.8M | -$10.8M | -$8.3M | — |
| Gross margin | 86.8% | 86.2% | 86.7% | 83.5% | 83.9% | — |
| Gross profit | $9.9M | $7.7M | $11.4M | $9.7M | $9.4M | — |
| Operating income | -$9.8M | -$8.4M | -$3.3M | -$9.0M | -$7.3M | — |
- Revenue +28% vs prior quarter ($11M vs $8.9M).
- Gross margin 86.8% (was 86.2% prior quarter).
- Operating margin expanded to -86%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $45.2M | $29.4M | $18.5M | $12.4M | — |
| Op margin | -59.7% | -122.9% | -294.3% | -293.9% | — |
| Net income | -$39.2M | -$30.0M | -$59.4M | -$47.2M | — |
| Gross margin | 84.6% | 86.1% | 85.9% | 81.8% | — |
| Gross profit | $38.2M | $25.3M | $15.9M | $10.1M | — |
| Operating income | -$26.9M | -$36.2M | -$54.5M | -$36.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Update: TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance
2026-09-23 · TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance
2026-09-23 · Top Premarket Gainers
2026-09-22 · TriSalus Life Sciences Gets FDA Clearance for TriNav Advance
2026-08-31 · TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
2026-08-18 · TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
2026-08-07 · TriSalus Life Sciences Q2 Earnings Call Highlights
2026-08-07 · TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...
2026-08-06 · TriSalus Life Sciences Reports Second Quarter 2026 Results
2026-08-05 · Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Q2 2026 -- GF Value Sees 20% Upside
2026-07-29 · TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Price (daily)
Full chart · RSI · MACD · patterns